NCT02326974 2026-04-17
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT06663787 2026-04-13
HER2 CR
Nagoya City University
Active not recruiting
NCT05323955 2026-03-17
BRIDGET
Duke University
Phase 2 Active not recruiting
NCT02675829 2026-03-04
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07421141 2026-02-27
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Active not recruiting
NCT03587740 2026-02-17
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04733118 2025-11-20
PHERGAIN-2
MedSIR
Phase 2 Active not recruiting
NCT04457596 2025-10-29
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT02314481 2025-05-23
DARWINII
University College, London
Phase 2 Active not recruiting
NCT02568839 2020-08-13
PREDIX HER2
Karolinska University Hospital
Phase 2/3 Active not recruiting